Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26022724 | 0.89 | HSD11B1 (0.37) | NPY5RMAPK1ALDH1A1POLBOPRM1 | |
| SCHEMBL6290482 | 0.79 | HSD11B1 (0.34) | NPY5RMAPK1ALDH1A1POLBOPRM1 | |
| SCHEMBL5827421 | 0.75 | CDA (0.44) | CDANPY5RALDH1A1F10SMN1; SMN2 | |
| SCHEMBL26022764 | 0.75 | MAPK1 (0.41) | NPY5RMAPK1LMNA | |
| SCHEMBL17138754 | 0.74 | CDA (0.42) | CDANPY5RMAPK1ALDH1A1F10 | |
| SCHEMBL19271812 | 0.74 | CDA (0.42) | CDANPY5RALDH1A1F10OPRM1 | |
| SCHEMBL17396031 | 0.73 | CDA (0.46) | CDANPY5RALDH1A1POLBF10 | |
| SCHEMBL17396030 | 0.73 | CDA (0.46) | CDANPY5RALDH1A1POLBF10 | |
| SCHEMBL11215508 | 0.72 | CDA (0.44) | CDANPY5RALDH1A1POLBF10 | |
| SCHEMBL8340922 | 0.71 | ADORA2A (0.39) | CDANPY5RF10LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | CDA 4883/4885NPY5R 2276/4885MAPK1 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.